And following through with uplisting? :-) It's enough to submit for that don't you think? And so far, so good. Cellceutix is on the right path and in the short term we'll know even more.
jmho, finra screwed a lot of companies over with their "lets save the weak" bs imo. Not that hard to do DD on a company on the OTC. If you can't find something then there's probably a reason. Cellceutix is FULLY reporting and transparent. I was hoping to have this vote/survey put this topic to rest. But, it may stick around until we're moving from $7 to $13 and having a glass of scotch while we're reading the up list PR for the 10thy time.
jmo.
Market Data 
Markets 
AI
